$155.72 +1.74 (%) Amgen Inc - NASDAQ

Aug. 27, 2015 | 04:00 PM

Partner Headlines

  1. The Other Bearish Biotech ETF Is Looking Groovy, Too

    Benzinga | Aug. 21, 2015 | 15:24PM EST
  2. These 6 Stocks Skyrocketed During The 2008 Crash

    Benzinga | Aug. 21, 2015 | 14:22PM EST
  3. Dan Loeb Is Still Bullish On Amgen, Allergan and Dow Chemical

    Benzinga | Aug. 18, 2015 | 16:33PM EST
  4. The Best Companies of the Pharmaceuticals Industry - August 2015

    GuruFocus | Aug. 18, 2015 | 13:50PM EST
  5. What Are Payors Saying About Managed Care Giants?

    Benzinga | Aug. 13, 2015 | 09:31AM EST
  6. The Historical Correlation Between Biotech Stocks And Interest Rates

    Benzinga | Aug. 7, 2015 | 14:39PM EST
  7. These Two Biotechs Boast Big EPS Growth Rates

    IBD | Aug. 6, 2015 | 11:14AM EST
  8. Allergan Q2 Beats, But Generics Sale Clouds Outlook

    IBD | Aug. 6, 2015 | 11:07AM EST
  9. What Company Will Be Fastest Growing Big-Cap Biotech?

    IBD | Aug. 5, 2015 | 14:58PM EST
  10. Social Media Beat: What The Crowd & Experts Think Of Oil, Biotech & LinkedIn

    Benzinga | Aug. 3, 2015 | 09:34AM EST
  11. Amgen Stock Hits High As Street Eyes Growth Drivers

    IBD | Jul. 31, 2015 | 11:20AM EST
  12. Stocks Open Mixed, Dow Lags; Expedia, Amgen, NewLink Rising

    IBD | Jul. 31, 2015 | 10:37AM EST
  13. Stock Futures Reverse Higher; Skywest, LinkedIn, Expedia In Motion

    IBD | Jul. 31, 2015 | 09:19AM EST
  14. Fast Money Picks For July 31

    Benzinga | Jul. 31, 2015 | 06:39AM EST
  15. 7 Must Watch Stocks for Today

    Benzinga | Jul. 31, 2015 | 04:18AM EST
  16. Amgen, Alexion Q2 Earnings Beat, But Guidance Differs

    IBD | Jul. 30, 2015 | 18:49PM EST
  17. Amgen, Alexion Profits Beat

    IBD | Jul. 30, 2015 | 18:47PM EST
  18. Stocks Finished Mixed; LinkedIn Leaps, Then Gives It Back

    IBD | Jul. 30, 2015 | 17:04PM EST
  19. Thursday's After-Hours Movers: Earnings Shaking LinkedIn, Expedia, EA, Amgen & Boston Beer Co

    Benzinga | Jul. 30, 2015 | 16:53PM EST
  20. Amgen Posts Upbeat Q2 Results, Lifts 2015 Guidance

    Benzinga | Jul. 30, 2015 | 16:46PM EST
  21. Stocks Stay Mixed; Cavium Reverses Higher

    IBD | Jul. 30, 2015 | 14:53PM EST
  22. Even With Recent Declines, Investors Still Love Biotech ETFs

    Benzinga | Jul. 30, 2015 | 14:52PM EST
  23. Gilead Gets Wall Street Love After Q2 Earnings Beat

    IBD | Jul. 29, 2015 | 12:29PM EST
  24. Amgen Stock Clears Buy Point Ahead Of Earnings

    IBD | Jul. 28, 2015 | 14:33PM EST
  25. Is More M&A On The Way For Large-Cap Biotechs?

    Benzinga | Jul. 28, 2015 | 13:18PM EST
  26. Biotech NantKwest Stock Surges On 1st Day Of Trading

    IBD | Jul. 28, 2015 | 12:08PM EST
  27. Benzinga's M&A Chatter for Monday July 27, 2015

    Benzinga | Jul. 27, 2015 | 18:39PM EST
  28. A Big Day For Biotech And It's Not Going So Well

    Benzinga | Jul. 27, 2015 | 13:10PM EST
  29. Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK

    IBD | Jul. 24, 2015 | 16:11PM EST
  30. US Stock Futures Mixed; All Eyes On Apple, Microsoft Earnings

    Benzinga | Jul. 21, 2015 | 07:10AM EST
  31. Why Big Biotech Could Have Another Leg Up

    Benzinga | Jul. 17, 2015 | 10:49AM EST
  32. Perrigo Company Is Strong But Overvalued

    GuruFocus | Jul. 15, 2015 | 13:02PM EST
  33. Regeneron, Amgen Downgraded As Biotech Seen Slowing

    IBD | Jul. 9, 2015 | 11:12AM EST
  34. Benzinga's Top Downgrades

    Benzinga | Jul. 9, 2015 | 09:26AM EST
  35. Large-Cap Biotechs Poised For Second-Half Rally, RBC Says

    Benzinga | Jul. 9, 2015 | 09:21AM EST
  36. Benzinga's Top #PreMarket Losers

    Benzinga | Jul. 9, 2015 | 08:19AM EST
  37. UBS Downgrades Amgen On 'Waiting Game,' Removes Brodalumab From Model

    Benzinga | Jul. 9, 2015 | 08:15AM EST
  38. US Stock Futures Jump Ahead Of Jobless Claims Data

    Benzinga | Jul. 9, 2015 | 07:41AM EST
  39. What Is Beyond Vision-Loss Blockbuster For Regeneron?

    IBD | Jul. 1, 2015 | 16:12PM EST
  40. Amgen Among 3 Medical Giants With Healthy Payouts

    IBD | Jun. 30, 2015 | 18:33PM EST
  41. Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent

    Benzinga | Jun. 29, 2015 | 14:44PM EST
  42. Biotech Short-Sellers Prefer Amgen To Gilead Sciences

    Benzinga | Jun. 27, 2015 | 18:02PM EST
  43. Alder Bio Up As Credit Suisse Lauds Migraine Drug

    IBD | Jun. 24, 2015 | 15:49PM EST
  44. ProShares Releases 2 New Leveraged Biotech ETFs

    Benzinga | Jun. 23, 2015 | 15:38PM EST
  45. An Ebola-Fighting Portfolio For The Present...And The Future

    Benzinga | Jun. 19, 2015 | 10:04AM EST
  46. Teva Migraine Drug Succeeds In Midstage Trial

    IBD | Jun. 18, 2015 | 17:57PM EST
  47. Biotech ETFs Hit New 2015 Highs

    Benzinga | Jun. 18, 2015 | 14:20PM EST
  48. Teva Migraine Drug Succeeds In Midstage Trial

    IBD | Jun. 18, 2015 | 12:27PM EST
  49. Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks

    GuruFocus | Jun. 11, 2015 | 13:41PM EST
  50. Why Drugmaker AbbVie Can Power Past Patent Expiration

    IBD | Jun. 11, 2015 | 13:13PM EST
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!